COVID-19 in patients with myasthenia gravis: Epidemiology and disease course.

Pietro BusinaroGloria VaghiEnrico MarchioniLuca DiamantiSebastiano ArceriPaola BiniElena ColomboGiuseppe CosentinoEnrico AlfonsiAlfredo CostaSabrina RavagliaGiulia MallucciElena BallanteDiego FranciottaMatteo Gastaldi

Published in: Muscle & nerve (2021)

The risk of COVID-19 in MG patients seems to be no higher than that of the general population, regardless of immunosuppressive therapies. In our cohort, COVID-19 barely affected MG course.

Keyphrases

coronavirus disease
sars cov
myasthenia gravis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
respiratory syndrome coronavirus
peritoneal dialysis
prognostic factors
risk factors